Enterobacter spp.: Update on Taxonomy, Clinical Aspects, and Emerging Antimicrobial Resistance
A Davin-Regli, JP Lavigne… - Clinical microbiology …, 2019 - Am Soc Microbiol
The genus Enterobacter is a member of the ESKAPE group, which contains the major
resistant bacterial pathogens. First described in 1960, this group member has proven to be …
resistant bacterial pathogens. First described in 1960, this group member has proven to be …
Multidrug-Resistant Enterobacter cloacae Complex Emerging as a Global, Diversifying Threat
MK Annavajhala, A Gomez-Simmonds… - Frontiers in …, 2019 - frontiersin.org
The Enterobacter cloacae complex (ECC) includes common nosocomial pathogens capable
of producing a wide variety of infections. Broad-spectrum antibiotic resistance, including the …
of producing a wide variety of infections. Broad-spectrum antibiotic resistance, including the …
Current epidemiology, genetic evolution and clinical impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae
Y Chong, S Shimoda, N Shimono - Infection, Genetics and Evolution, 2018 - Elsevier
The worldwide spread of extended-spectrum β-lactamase (ESBL)-producing bacteria,
particularly Escherichia coli and Klebsiella pneumoniae, is a critical concern for the …
particularly Escherichia coli and Klebsiella pneumoniae, is a critical concern for the …
IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections
JS Solomkin, J Gardovskis, K Lawrence… - Clinical Infectious …, 2019 - academic.oup.com
Background Increasing antimicrobial resistance among pathogens that cause complicated
intraabdominal infections (cIAIs) supports the development of new antimicrobials …
intraabdominal infections (cIAIs) supports the development of new antimicrobials …
Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance …
KM Kazmierczak, JA Karlowsky… - Antimicrobial agents …, 2021 - Am Soc Microbiol
To estimate the incidence of carbapenem-resistant Enterobacterales (CRE), a global
collection of 81,781 surveillance isolates of Enterobacterales collected from patients in 39 …
collection of 81,781 surveillance isolates of Enterobacterales collected from patients in 39 …
Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia
SS Jean, YC Chang, WC Lin, WS Lee… - Journal of clinical …, 2020 - mdpi.com
Septicaemia likely results in high case-fatality rates in the present multidrug-resistant (MDR)
era. Amongst them are hospital-acquired pneumonia (HAP) and ventilator-associated …
era. Amongst them are hospital-acquired pneumonia (HAP) and ventilator-associated …
Whole genome analyses of CMY-2-producing Escherichia coli isolates from humans, animals and food in Germany
M Pietsch, A Irrgang, N Roschanski, G Brenner Michael… - BMC genomics, 2018 - Springer
Background Resistance to 3rd-generation cephalosporins in Escherichia coli is mostly
mediated by extended-spectrum beta-lactamases (ESBLs) or AmpC beta-lactamases …
mediated by extended-spectrum beta-lactamases (ESBLs) or AmpC beta-lactamases …
[HTML][HTML] Genomic epidemiology of global carbapenemase-producing Enterobacter spp., 2008–2014
We performed whole-genome sequencing on 170 clinical carbapenemase-producing
Enterobacter spp. isolates collected globally during 2008–2014. The most common …
Enterobacter spp. isolates collected globally during 2008–2014. The most common …
Carbapenem and colistin resistance in Enterobacteriaceae in Southeast Asia: review and mapping of emerging and overlapping challenges
MD Malchione, LM Torres, DM Hartley, M Koch… - International journal of …, 2019 - Elsevier
Carbapenem-resistant Enterobacteriaceae infections have spread globally, leaving
polymyxins, including colistin, as 'last-resort treatments'. Emerging colistin resistance raises …
polymyxins, including colistin, as 'last-resort treatments'. Emerging colistin resistance raises …
[HTML][HTML] A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated …
X Qin, BG Tran, MJ Kim, L Wang, DA Nguyen… - International journal of …, 2017 - Elsevier
Ceftazidime/avibactam comprises the broad-spectrum cephalosporin ceftazidime and the
non-β-lactam β-lactamase inhibitor avibactam. This phase 3, randomised, double-blind …
non-β-lactam β-lactamase inhibitor avibactam. This phase 3, randomised, double-blind …